The antitrust case focuses on a series of settlements that occurred in the late 1990s between Bayer and Barr Pharmaceuticals, which Teva acquired in 2008. Bayer allegedly paid Barr $398 million to keep the generic version of Cipro off the market. Bayer had also previously sued Barr claiming the generic antibiotic would infringe on a Bayer patent for Cipro, according to the report.
A group of nonprofits and individuals in California filed the suit in California state court in 2000, claiming the original settlement drove up the price of the antibiotic and violated the state’s antitrust laws.
The settlement is still pending approval from California’s highest court, according to the report.
More articles on supply chain:
17 pharma companies’ stock prices dropped after Trump’s ‘getting away with murder’ speech
Trump administration proposes 20% tax on Mexican goods: 5 things to know
Prologis CEO: Warehouse shortage coming to an end
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
